Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）

Inclusion Criteria: * Healthy people aged over 16 years old at the time of the first vaccination, normal intelligence and agree to sign the informed consent form. * Healthy subjects as established by medical history and history-oriented clinical examination before entering into the study. * Subjects will reside in the study region in the next 7 months. * Free of history of hepatitis E. * Can comply with the request of study. * Axillary temperature is below 37 degree centigrade. Exclusion Criteria: For dose 1: * receiving other vaccine or immunoglobulin within two weeks; * Having serious allergic history to vaccine and medicine * Eclampsia, epilepsy, encephalopathy and history of mental disease or family; * Thrombocytopenia or other disturbance of blood coagulation which would lead to muscle injection taboo; * Fixed or suspected deficiency of immunologic function, containing immunosuppressant treatment, genetic defect, HIV or other factors; * Congenital malformation, eccyliosis or severe chronic disease; * Fixed or suspected other disease including fever, active infection, liver and kidney disease, angiocardiopathy, malignancy, acute and chronic disease; * joining other clinical study undergoing; * women pregnant or in lactation. For dose 2 or 3: * Severe allergy for dose 1 or 2; * Severe adverse reaction associated with last vaccination; * New occurrence of symptoms meet dose 1 exclusion criteria after the first dose.